Last reviewed · How we verify

JLP-1310, Fasted followed by fed

Jeil Pharmaceutical Co., Ltd. · Phase 1 active Small molecule

JLP-1310, Fasted followed by fed is a Small molecule drug developed by Jeil Pharmaceutical Co., Ltd.. It is currently in Phase 1 development. Also known as: metformin hydrochloride, rosuvastatin calcium.

At a glance

Generic nameJLP-1310, Fasted followed by fed
Also known asmetformin hydrochloride, rosuvastatin calcium
SponsorJeil Pharmaceutical Co., Ltd.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about JLP-1310, Fasted followed by fed

What is JLP-1310, Fasted followed by fed?

JLP-1310, Fasted followed by fed is a Small molecule drug developed by Jeil Pharmaceutical Co., Ltd..

Who makes JLP-1310, Fasted followed by fed?

JLP-1310, Fasted followed by fed is developed by Jeil Pharmaceutical Co., Ltd. (see full Jeil Pharmaceutical Co., Ltd. pipeline at /company/jeil-pharmaceutical-co-ltd).

Is JLP-1310, Fasted followed by fed also known as anything else?

JLP-1310, Fasted followed by fed is also known as metformin hydrochloride, rosuvastatin calcium.

What development phase is JLP-1310, Fasted followed by fed in?

JLP-1310, Fasted followed by fed is in Phase 1.

Related